Topic

Aetna (CVS Health)

A collection of 1351 issues

How to Get Vitrakvi (Larotrectinib) Covered by Aetna CVS Health in Washington: PA Forms, Appeals, and Cost-Saving Strategies

Answer Box: Getting Vitrakvi Covered by Aetna CVS Health in Washington Aetna CVS Health requires prior authorization for Vitrakvi (larotrectinib) with NTRK gene fusion testing documentation. Submit PA via CVS Specialty at 1-888-267-3277 with molecular pathology report showing NTRK1/2/3 fusion, oncologist prescription, and staging records. If denied, Washington
7 min read

How to Get Elevidys Gene Therapy Covered by Aetna CVS Health in New York: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Started To get Elevidys (delandistrogene moxeparvovec-rokl) covered by Aetna CVS Health in New York: Submit prior authorization through the Availity portal with genetic confirmation, ambulatory status documentation, and approved infusion center verification. If denied, file internal appeal within 180 days, then New York external appeal within 4
6 min read

How to Get Pomalyst (Pomalidomide) Covered by Aetna (CVS Health) in Texas: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Pomalyst (Pomalidomide) Covered by Aetna (CVS Health) in Texas Aetna (CVS Health) requires prior authorization for Pomalyst (pomalidomide) with documented failure of both lenalidomide and a proteasome inhibitor, plus mandatory PS-Pomalidomide REMS enrollment. To get approval in Texas: (1) Complete REMS certification through the BMS portal within
6 min read

Renewing Orfadin (nitisinone) Approval with Aetna (CVS Health) in New Jersey: Timeline, Documentation & Appeal Process

Answer Box: Key Steps for Orfadin Renewal Success Orfadin (nitisinone) is excluded from Aetna's 2025 specialty formulary, requiring a formulary exception for any coverage. Start renewal 60-90 days early with updated labs (succinylacetone, tyrosine levels, liver function tests), metabolic specialist notes documenting treatment response, and dietary compliance records.
6 min read